# EDGAR Filing Document

**Accession Number:** 0001020214
**File Stem:** 0001193125-26-009824
**Filing Date:** 2026-1
**Character Count:** 20895
**Document Hash:** 77b8984598f86ed15e66e29e1d6a1208
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-009824.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001193125-26-009824

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260111

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CERUS CORP
- **CENTRAL INDEX KEY:** 0001020214
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 680262011
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21937
- **FILM NUMBER:** 26524759

**BUSINESS ADDRESS:**
- **STREET 1:** 1220 CONCORD AVENUE
- **STREET 2:** SUITE 600
- **CITY:** CONCORD
- **STATE:** CA
- **ZIP:** 94520
- **BUSINESS PHONE:** 9252886000

**MAIL ADDRESS:**
- **STREET 1:** 1220 CONCORD AVENUE
- **STREET 2:** SUITE 600
- **CITY:** CONCORD
- **STATE:** CA
- **ZIP:** 94520

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CERUS TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19960731

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 11, 2026<br>

------

CERUS CORPORATION

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-21937 | 68-0262011 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 1220 Concord Avenue, Suite 600 |  |  |
| Concord**,** California |  | 94520 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 925 288-6000<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | CERS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.
On January 11, 2026, Cerus Corporation (the "Company") announced its preliminary product revenue results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the Company's press release, entitled "Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Such product revenue results as reported are preliminary, unaudited and subject to completion. The Company's independent registered public accounting firm has not audited or performed any procedures with respect to these preliminary results and does not express an opinion or any other form of assurance with respect thereto. The Company's financial closing procedures for the three months and year ended December 31, 2025 are not yet complete and, as a result, the final results upon completion of the closing procedures may vary from the preliminary estimates, and any such differences may be material. The Company's product revenue information presented herein should not be viewed as a substitute for the information set forth in the full financial statements prepared in accordance with U.S. generally accepted accounting principles, and undue reliance should not be placed on these preliminary product revenue results.

The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

The following exhibit is furnished with this report:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 <u>Press release, dated January 11, 2026, entitled "</u>[<u>Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook</u>](cers-ex99_1.htm)<u>."</u>

104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | CERUS CORPORATION |
| Date: | January 11, 2026 | By:  | /s/ Kevin D. Green |
|  |  |  | Kevin D. Green<br>Chief Financial Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img34436962_0.jpg](img34436962_0.jpg)

**Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook** 

*Preliminary Full-Year 2025 Product Revenue of $206.1 Million* 

*Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year*

CONCORD, CA, January 11, 2026 - Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026.

"2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world," said William "Obi" Greenman, Cerus' president and chief executive officer. "During 2025, based on the number of kits sold, we helped our blood center customers produce approximately 3 million INTERCEPT treated blood component doses for patients in about 40 countries worldwide. We remain focused on supporting blood centers around the globe in their daily mission to ensure robust blood safety and availability. We expect 2026 to be a year rich in milestones for Cerus, as we continue to expand our commercial reach, advance our product development pipeline and continue improving Cerus' financial performance and position."

Preliminary Fourth Quarter and Full-Year 2025 Financial Results & 2026 Outlook

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Preliminary fourth quarter 2025 product revenue totaled $57.8 million representing an increase of 14% compared to the fourth quarter of 2024. Included in these results, preliminary product revenue results from INTERCEPT Fibrinogen Complex, or IFC, were $4.2 million, representing a year-over-year increase of around 40%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Preliminary full-year 2025 product revenue totaled $206.1 million, representing an increase of 14% over 2024 results. Included in the full-year 2025 preliminary product revenue results were $16.7 million contribution from IFC, representing a year-over-year increase of approximately 80%. The preliminary fourth quarter and full-year 2025 product revenue results have not been audited and are therefore subject to change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Looking ahead, the Company expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing year-over-year growth of 9%-11% compared to preliminary unaudited 2025 product revenue. Included in the 2026 guidance range is expected full-year 2026 IFC revenue of $20 million to $22 million, representing year-over-year growth of approximately 20% to 30% from 2025.

Anticipated 2026 development and clinical milestones:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Premarket Approval (PMA) application submission to the FDA for INT200, the next generation LED-based illumination device, expected in mid-2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Results from the Phase 3 RedeS study of the INTERCEPT Blood System for Red Blood Cells (RBCs) in anemia patients expected in the second half of 2026.

------

Cerus plans to provide complete fourth quarter and full-year 2025 financial results and to discuss those results and provide a general business overview on a hosted call in early March 2026.

A comparative breakdown of the preliminary fourth quarter and full-year 2025 product revenue compared to 2024 product revenue is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** | &nbsp;&nbsp;&nbsp;**CERUS CORPORATION** |
| &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** | &nbsp;&nbsp;&nbsp;**PRODUCT REVENUE** |
| &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** | &nbsp;&nbsp;&nbsp;**(in millions, except percentages)** |
|  | &nbsp;&nbsp;&nbsp;**Three Months Ended** | &nbsp;&nbsp;&nbsp;**Three Months Ended** |  | &nbsp;&nbsp;&nbsp;**Twelve Months Ended** | &nbsp;&nbsp;&nbsp;**Twelve Months Ended** |  |
|  | &nbsp;&nbsp;&nbsp;**December 31,** | &nbsp;&nbsp;&nbsp;**December 31,** | &nbsp;&nbsp;&nbsp;**Change** | &nbsp;&nbsp;&nbsp;**December 31,** | &nbsp;&nbsp;&nbsp;**December 31,** | &nbsp;&nbsp;&nbsp;**Change** |
|  | &nbsp;&nbsp;&nbsp;**2025\*** | &nbsp;&nbsp;&nbsp;**2024** | $&nbsp;&nbsp;&nbsp;**%** | &nbsp;&nbsp;&nbsp;**2025\*** | &nbsp;&nbsp;&nbsp;**2024** | $&nbsp;&nbsp;&nbsp;**%** |
| &nbsp;&nbsp;&nbsp;Platelets, Plasma, Other | &nbsp;&nbsp;&nbsp; $53.6  | &nbsp;&nbsp;&nbsp; $47.8  | &nbsp;&nbsp;&nbsp;12% | &nbsp;&nbsp;&nbsp; $189.4  | &nbsp;&nbsp;&nbsp; $171.1  | &nbsp;&nbsp;&nbsp;11% |
| &nbsp;&nbsp;&nbsp;IFC | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.2  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.0  | &nbsp;&nbsp;&nbsp;40% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16.7  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2  | &nbsp;&nbsp;&nbsp;82% |
| &nbsp;&nbsp;&nbsp;Total product revenue | &nbsp;&nbsp;&nbsp; $57.8  | &nbsp;&nbsp;&nbsp; $50.8  | &nbsp;&nbsp;&nbsp;14% | &nbsp;&nbsp;&nbsp; $206.1  | &nbsp;&nbsp;&nbsp;$180.3  | &nbsp;&nbsp;&nbsp;14% |
| &nbsp;&nbsp;\*Unaudited preliminary results only. | &nbsp;&nbsp;\*Unaudited preliminary results only. | &nbsp;&nbsp;\*Unaudited preliminary results only. |  |  |  |  |
| &nbsp;&nbsp;Percentages calculated from unrounded figures. | &nbsp;&nbsp;Percentages calculated from unrounded figures. | &nbsp;&nbsp;Percentages calculated from unrounded figures. | &nbsp;&nbsp;Percentages calculated from unrounded figures. | &nbsp;&nbsp;Percentages calculated from unrounded figures. |  |  |

---

**ABOUT CERUS**

Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

**Forward-Looking Statements** 

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to: Cerus' preliminary fourth quarter and full-year 2025 product revenue; Cerus' 2026 annual product revenue guidance; Cerus' expectation that, in 2026, it will continue to expand its commercial reach, advance its product development pipeline and continue improving its financial performance and position; Cerus' expectations with respect to the timing of its PMA application submission to the FDA for INT200 and results from the Phase 3 RedeS study of the INTERCEPT Blood System for RBCs in anemia

------

patients; and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: the risks that Cerus may not (a) meet its 2026 annual product revenue guidance, (b) effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus' commercial agreements with these customers, (e) effectively expand its commercialization activities into additional geographies and/or (f) realize any revenue contribution from new product offerings, whether due to Cerus' inability to obtain regulatory approval of its pipeline programs, or otherwise; the risk that the U.S. RedeS study may take longer than Cerus expects or may not be completed at all or, if completed, may not demonstrate the safety and/or efficacy of the INTERCEPT Blood System for RBCs; risks associated with macroeconomic developments, including ongoing military conflict in Ukraine, new or increased tariffs and escalating trade tensions and the resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus' business operations; risks related to Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time-consuming development and regulatory process, including the risk that Cerus may be unable to obtain and maintain the requisite regulatory approvals necessary to commercialize the INT200 and/or advance its pipeline programs and bring them to market in a timely manner or at all, including the risk that Cerus' PMA application for INT200 may not be submitted to the FDA on the timeline Cerus anticipates or at all; risks related to product safety; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from military conflicts, rising interest rates, inflation, new or increased tariffs and escalating trade tensions or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus' reliance on third parties to market, sell, distribute and maintain its products; risks associated with Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus' supply chain could be negatively impacted as a result of the evolving impact of macroeconomic developments, including the ongoing military conflict in Ukraine, rising interest rates, inflation, and new or increased tariffs and escalating trade tensions, (b) Cerus' manufacturers could be unable to comply with extensive regulatory agency requirements, and (c) Cerus may be unable to maintain its supply agreements with its third party suppliers; risks associated with Cerus' need for additional funding; risks associated with the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus' future capital requirements and its future revenues and other financial performance and results, including as it relates to Cerus' 2026 annual product revenue guidance; as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in Cerus' Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

------

This press release includes Cerus' preliminary product revenue results for the quarter and year ended December 31, 2025. Cerus is currently in the process of finalizing its full financial results for the quarter and year ended December 31, 2025, and the preliminary product revenue results presented in this press release are based only upon preliminary information available to Cerus as of January 11, 2026. Cerus' preliminary product revenue results should not be viewed as a substitute for full audited financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Cerus' preliminary product revenue results. In addition, Cerus' independent registered public accounting firm has not audited or reviewed the preliminary product revenue results included in this press release or expressed any opinion or other form of assurance on such preliminary product revenue results. In addition, items or events may be identified or occur after the date hereof due to the completion of operational and financial closing procedures, final audit adjustments and other developments may arise that would require Cerus to make material adjustments to the preliminary product revenue results included in this press release. Therefore, the preliminary product revenue results included in this press release may differ, perhaps materially, from the product revenue results that will be reflected in Cerus' audited consolidated financial statements for the year ended December 31, 2025.

Contact:

Tim Lee – Head of Investor Relations

Cerus Corporation

ir@cerus.com

925-288-6128

------